



# Asymmetric Organocatalysts




# Asymmetric Organocatalysts

Asymmetric organocatalysis has emerged as a powerful synthetic tool that is complementary to metal-catalyzed reactions. Pioneering work in this area dates back to the 1970s in which Eder *et al.* and Hajos *et al.* separately reported an intramolecular asymmetric aldol reaction which employed L-proline [P0481] as catalyst.<sup>1,2)</sup> This reaction was considered to be a special case at that time. Later in 2000, List *et al.* reported an L-proline-catalyzed intermolecular asymmetric aldol reaction.<sup>3)</sup> The same year, MacMillan *et al.* documented the first highly enantioselective amine-catalyzed Diels-Alder reaction.<sup>4)</sup> These reports received a great deal of attention and the research in the area of asymmetric organocatalysts has since thrived.<sup>5)</sup>




Later, the significance of these proline-catalyzed reactions was luminously demonstrated by MacMillan for the application to carbohydrate synthesis.<sup>6)</sup> Córdova *et al.* reported a proline-catalyzed asymmetric conversion of protected glycol aldehydes into hexoses in one step.<sup>7)</sup>





Compared with conventional transition metal complex catalysts, asymmetric organocatalysts offer several advantages including operational simplicity, their availability, and low toxicity which confer a direct benefit in the production of pharmaceuticals and contribution to green chemistry.


In the initial spectacular advances in asymmetric organocatalysis, proline and its analogues have been predominantly employed. Generally organocatalytic aldol reactions with ketones as acceptors require high catalyst loadings, however a recent development in this area enables the reaction with a lower catalyst loading. Nakamura *et al.* reported the enantioselective synthesis of (*R*)-convolutamydine by using 5 mol% of newly developed novel *N*-heteroaryl-sulfonylprolinamide [T3080].<sup>8)</sup> In this reaction, amounts of the catalyst can be reduced to 0.5 mol% with retention of the enantioselectivity even though the time takes longer to complete the reaction.




Singh *et al.* also developed a new class of proline-based organocatalysts and reported asymmetric direct aldol reactions with excellent enantioselectivities (>99% ee). A variety of ketones and aldehydes could be employed using 0.5 mol% of catalyst [H1407].<sup>9)</sup>





Due to the various advantages including ready availability and versatility, the asymmetric reactions using other amino acids as organocatalysts were also intensively studied. More recently, the group of Lu explored the possibility of deriving a wide array of novel multifunctional organocatalysts from amino acid structural scaffolds.<sup>10)</sup> The new catalyst, dipeptide-derived phosphine [T2937], was proven to promote enantioselective [3+2] cycloadditions of Allenes to acrylates or acrylamides.




Cinchona alkaloids and their derivatives have been intensively used as chiral ligands for metal-catalyzed reactions or as organocatalysts as demonstrated in Sharpless asymmetric dihydroxylation with an OsO<sub>4</sub>-cinchona alkaloids complex.<sup>11)</sup> It is considered as one of the most privileged chiral inducers. Cinchona alkaloids-derived catalysts could be effectively applied for nearly all classes of organic reactions. The quinuclidinyl moiety as a tertiary amine could serve as an active center for Brønsted base catalysis, Lewis base catalysis, and nucleophilic catalysis. Upon alkylation of the quinuclidine nitrogen, the resulting ammonium salts could serve as phase transfer catalysts, another class of organic catalysis. Hatakeyama, Ishihara, et al. have developed  $\alpha$ -isocupreine ( $\alpha$ -ICPN) [E0974], a pseudoenantiomer of  $\beta$ -isocupreidine [I0728] and reported the application to an efficient asymmetric Morita-Baylis-Hillman (MBH) reaction.<sup>12)</sup>




Since the pioneering work on asymmetric synthesis of amino acids using *N*-benzyl cinchoninium halide as a chiral phase transfer catalyst in 1980s,<sup>13)</sup> numerous cinchona alkaloids-derived chiral phase-transfer catalysts have been developed.<sup>14)</sup> In the late 1990s, a totally new aspect on the design of chiral phase-transfer catalyst, based on the *C*<sub>2</sub>-symmetrical chiral binaphthyl moiety, has emerged.<sup>15)</sup> The ongoing efforts towards the simplification of the catalyst have led to the novel catalyst which could be employed under even milder conditions with excellent enantioselectivities. Maruoka et al. reported an enantioselective conjugate addition of 3-substituted oxindoles to Michael acceptors under neutral conditions in a water-rich solvent in the presence of a newly developed morpholine-derived chiral phase-transfer catalyst [B3970] without base additives.<sup>16)</sup>




Nucleophilic carbene is an emerging class of asymmetric organocatalysis. Since the report of the first asymmetric intramolecular Stetter reaction by Enders et al., there have been many reports on asymmetric carbon-carbon bond formation reactions *via* umpolung of aldehydes mediated by *N*-heterocyclic carbene (NHC) catalysts.<sup>17)</sup> Bode et al. have reported highly enantioselective Diels–Alder reactions to afford dihydropyridinones using an NHC catalyst [D3983] generated *in situ*.<sup>18)</sup>




The imidazolidinone derivatives [B4137] [B4138] are asymmetric organocatalysts developed by MacMillan et al. To date, various types of asymmetric reactions using B4137 and B4138 have been reported, such as Mukaiyama-Michael addition,<sup>19)</sup> epoxidation of  $\alpha,\beta$ -unsaturated aldehydes,<sup>20)</sup> 1,3-addition of aldehydes,<sup>21)</sup> and the Diels-Alder reaction.<sup>22)</sup> The desired products are realized in high yields and selectivity in all the cases. These reactions are often utilized in total syntheses of natural products to construct complex condensed-ring structures such as in spinosyn.<sup>23)</sup> Thus, B4137 and B4138 are powerful tools and their use in new asymmetric reactions is anticipated.



The two prolinol derivatives **D3867** and **D3843**, known as Hayashi-Jørgensen catalysts are utilized in various types of asymmetric reactions. For instance, Hayashi *et al.* have reported an asymmetric Michael addition of nitroalkenes and aldehydes, which gives *syn* adducts with high enantio- and diastereoselectivities.<sup>25)</sup> Furthermore, utilizing this reaction as a key early-stage step allowed them to achieve a short synthesis of the anti-flu drug oseltamivir phosphate.<sup>25)</sup> Additionally, Jørgensen's group have reported a tandem Michael/intramolecular Morita-Baylis-Hillman reaction to afford cyclohexanone derivatives.<sup>26)</sup>



Ishihara's group has developed a new iodoarene catalyst **I1122** for the enantioselective spirolactonization.<sup>27)</sup> The given spirolactone has a diene moiety, so that it affords an optically active fused ring compound in one-pot synthesis through Diels-Alder reaction with an olefin. Furthermore, **I1122** is also utilized in the construction of asymmetric cyclic acetals.<sup>28)</sup>



## References





































- 1) U. Eder, G. Sauer, R. Wiechert, *Angew. Chem. Int. Ed.* **1971**, *10*, 496.
- 2) Z. G. Hajos, D. R. Parrish, *J. Org. Chem.* **1974**, *39*, 1615.
- 3) B. List, R. A. Lerner, C. F. Barbas III, *J. Am. Chem. Soc.* **2000**, *122*, 2395.
- 4) K. A. Ahrendt, C. J. Borths, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2000**, *122*, 4243.
- 5) S. Mukherjee, J. W. Yang, S. Hoffman, B. List, *Chem. Rev.* **2007**, *107*, 5471.
- 6) A. B. Northrup, D. W. C. MacMillan, *Science* **2004**, *305*, 1752.
- 7) A. Córdova, M. Engqvist, I. Ibrahim, J. Casas, H. Sundén, *Chem. Commun.* **2005**, 2047.
- 8) S. Nakamura, N. Hara, H. Nakashima, K. Kubo, N. Shibata, T. Toru, *Chem. Eur. J.* **2008**, *14*, 8079.
- 9) (a) H. Kyilmälä, A. Neuvonen, R. Jokela, *Int. J. Org. Chem.* **2013**, *3*, 162.  
(b) V. Maya, M. Raj, V. K. Singh, *Org. Lett.* **2007**, *9*, 2593.
- 10) (a) W. Yao, X. Dou, Y. Lu, *J. Am. Chem. Soc.* **2015**, *137*, 54.  
(b) X. Han, F. Zhong, Y. Wang, Y. Lu, *Angew. Chem. Int. Ed.* **2012**, *51*, 767.
- 11) (a) Cinchona Alkaloids in Synthesis and Catalysis, ed. by C. E. Song, John Wiley and Sons, **2009**.  
(b) Privileged Chiral Ligands and Catalysts, ed. by Q.-L. Zhou, John Wiley and Sons, **2011**.  
(c) S. G. Hentges, K. B. Sharpless, *J. Am. Chem. Soc.* **1980**, *102*, 4263.
- 12) Y. Nakamoto, F. Urabe, K. Takahashi, J. Ishihara, S. Hatakeyama, *Chem. Eur. J.* **2013**, *19*, 12653.
- 13) U.-H. Dolling, O. Davis, E. J. J. Grabowski, *J. Am. Chem. Soc.* **1984**, *106*, 446.
- 14) T. Hashimoto, K. Maruoka, *Chem. Rev.* **2007**, *107*, 5656.
- 15) T. Ooi, M. Kameda, K. Maruoka, *J. Am. Chem. Soc.* **1999**, *121*, 6519.
- 16) R. He, S. Shirakawa, K. Maruoka, *J. Am. Chem. Soc.* **2009**, *131*, 16620.
- 17) D. Enders, O. Niemeier, A. Henseler, *Chem. Rev.* **2007**, *107*, 5606.
- 18) (a) M. He, J. R. Struble, J. W. Bode, *J. Am. Chem. Soc.* **2006**, *128*, 8418.  
(b) M. He, G. J. Uc, J. W. Bode, *J. Am. Chem. Soc.* **2006**, *128*, 15088.
- 19) S. P. Brown, N. C. Goodwin, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2003**, *125*, 1192.
- 20) S. Lee, D. W. C. MacMillan, *Tetrahedron* **2006**, *62*, 11413.
- 21) H.-Y. Jang, J.-B. Hong, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2007**, *129*, 7004.
- 22) R. M. Wilson, W. S. Jen, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2005**, *127*, 11616.
- 23) Y. Bai, X. Shen, Y. Li, M. Dai, *J. Am. Chem. Soc.* **2016**, *138*, 10838.
- 24) Y. Hayashi, H. Gotoh, T. Hayashi, M. Shoji, *Angew. Chem. Int. Ed.* **2005**, *44*, 4212.
- 25) H. Ishikawa, T. Suzuki, Y. Hayashi, *Angew. Chem. Int. Ed.* **2009**, *48*, 1304.
- 26) S. Cabrera, J. Alemán, P. Bolze, S. Bertelsen, K. A. Jørgensen, *Angew. Chem. Int. Ed.* **2008**, *47*, 121.
- 27) M. Uyanik, T. Yasui, K. Ishihara, *Angew. Chem. Int. Ed.* **2013**, *52*, 9215.
- 28) M. Uyanik, N. Sasakura, M. Mizuno, K. Ishihara, *ACS Catal.* **2017**, *7*, 872.

# The list of products

We introduce our products according to their structure.


<b>Prolines, Proline Analogs</b> . . . . .	<b>7</b>
<b>Amino Acids</b> . . . . .	<b>8</b>
<b>Cinchona Alkaloids</b> . . . . .	<b>8</b>
<b>Chiral Imidazolidinones</b> . . . . .	<b>9</b>
<b>Chiral Oxazaborolidines</b> . . . . .	<b>9</b>
<b>Chiral Isothioureas</b> . . . . .	<b>9</b>
<b>Chiral Diols</b> . . . . .	<b>9</b>
<b>Chiral Phosphoric Acids</b> . . . . .	<b>10</b>
<b>Chiral Sulfonic Acids</b> . . . . .	<b>10</b>
<b>Chiral Amines</b> . . . . .	<b>10</b>
<b>Chiral Ammonium Salts</b> . . . . .	<b>10</b>
<b>Chiral N-Heterocyclic Carbenes (NHC)</b> . . . . .	<b>10</b>
<b>Others</b> . . . . .	<b>11</b>

## Prolines, Proline Analogs

<b>F0818</b> 50mg	<b>H0296</b> 5g 25g 100g	<b>P2083</b> 1g 5g	<b>P0481</b> 25g 250g	<b>P0994</b> 5g 25g
 <i>trans</i> -4-Fluoro-L-proline CAS RN: 2507-61-1	 <i>trans</i> -4-Hydroxy-L-proline CAS RN: 51-35-4	 D-Prolinamide CAS RN: 62937-45-5	 L-Proline CAS RN: 147-85-3	 D-Proline CAS RN: 344-25-2
<b>I0395</b> 1g 5g	<b>O0370</b> 1g 5g	<b>M2077</b> 1g 5g	<b>B3440</b> 1g 5g	<b>I0589</b> 1g
 (S)-(-)-Indoline-2-carboxylic Acid CAS RN: 79815-20-6	 (2 <i>S</i> ,3a <i>S</i> ,7a <i>S</i> )-Octahydro-1 <i>H</i> -indole-2-carboxylic Acid CAS RN: 80875-98-5	 $\alpha$ -Methyl-L-proline CAS RN: 42856-71-3	 <i>trans</i> -4-( <i>tert</i> -Butyl-diphenylsilyloxy)-L-proline CAS RN: 259212-61-8	 ( <i>R</i> )-(-)-Indoline-2-carboxylic Acid CAS RN: 98167-06-7
<b>A1301</b> 1g 5g	<b>A0945</b> 1g 5g	<b>P1382</b> 1g 5g 25g	<b>T3080</b> 100mg	<b>H1407</b> 200mg 1g
 (S)-(-)-2-Aminomethyl-1-ethyl-pyrrolidine CAS RN: 22795-99-9	 (S)-(+)-2-(Anilinomethyl)-pyrrolidine CAS RN: 64030-44-0	 L-Prolinamide CAS RN: 7531-52-4	 <i>N</i> -(2-Thiophenesulfonyl)-L-prolinamide CAS RN: 1089663-51-3	 Singh's Catalyst CAS RN: 910110-45-1
<b>M1169</b> 1g 5g	<b>M1161</b> 1g 5g	<b>P1925</b> 1g	<b>P1241</b> 1g 5g	<b>M1183</b> 1g 5g
 (R)-2-(Methoxymethyl)-pyrrolidine CAS RN: 84025-81-0	 (S)-2-(Methoxymethyl)-pyrrolidine CAS RN: 63126-47-6	 (R)-(-)-1-(2-Pyrrolidinylmethyl)pyrrolidine CAS RN: 60419-23-0	 (S)-(+)-1-(2-Pyrrolidinylmethyl)pyrrolidine CAS RN: 51207-66-0	 (S)-(-)-1-Methyl-2-(1-piperidinomethyl)pyrrolidine CAS RN: 84466-85-3
<b>H0768</b> 100mg 1g 5g	<b>D3843</b> 1g 5g	<b>D2365</b> 1g 5g	<b>D2735</b> 1g 5g	<b>H0784</b> 100mg 1g 5g
 (S)-(-)-2-[Hydroxy(diphenyl)methyl]-1-methylpyrrolidine CAS RN: 110529-22-1	 (S)-Hayashi-Jorgensen Catalyst CAS RN: 848821-58-9	 (R)-(+)- $\alpha,\alpha$ -Diphenyl-2-pyrrolidinemethanol CAS RN: 22348-32-9	 (S)-(-)- $\alpha,\alpha$ -Diphenyl-2-pyrrolidinemethanol CAS RN: 112068-01-6	 (R)-(-)-2-[Hydroxy(diphenyl)methyl]-1-methylpyrrolidine CAS RN: 144119-12-0
<b>B5882</b> 1g 5g	<b>D3185</b> 100mg	<b>D3867</b> 1g 5g	<b>D3804</b> 1g	<b>B5701</b> 1g
 (R)-Bis[3,5-bis(trifluoromethyl)phenyl](pyrrolidin-2-yl)methanol CAS RN: 948595-00-4	 (2 <i>R</i> ,5 <i>R</i> )-2,5-Diphenylpyrrolidine CAS RN: 155155-73-0	 (R)-Hayashi-Jorgensen Catalyst CAS RN: 943757-71-9	 (S)-(-)-2-(Diphenylmethyl)pyrrolidine CAS RN: 119237-64-8	 (S)- $\alpha,\alpha$ -Bis[3,5-bis(trifluoromethyl)phenyl]-2-pyrrolidinemethanol CAS RN: 848821-76-1
<b>P1404</b> 1g 5g	<b>T0219</b> 25g 500g	<b>P1784</b> 100mg 500mg	<b>A1043</b> 100mg 1g	<b>P1830</b> 5g 25g
 L-Pipeolic Acid CAS RN: 3105-95-1	 L-Thioproline CAS RN: 34592-47-7	 (S)-5-(Pyrrolidin-2-yl)-1 <i>H</i> -tetrazole CAS RN: 33878-70-5	 L-Azetidine-2-carboxylic Acid CAS RN: 2133-34-8	 D-Pipeolic Acid CAS RN: 1723-00-8
<b>M1995</b> 1g 5g			<b>T1515</b> 5g 25g	
		 (S)-2-[(1-Methyl-2-pyrrolidinyl)methyl]isoindoline Dihydrochloride · 2HCl	 (S)-(-)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid CAS RN: 74163-81-8	


## Amino Acids

**M0102** 1g 5g 25g




D-Methionine  
CAS RN: 348-67-4

**P0134** 25g 250g




L-Phenylalanine  
CAS RN: 63-91-2

**A0179** 25g 250g




L-Alanine  
CAS RN: 56-41-7

**A0177** 5g 25g




D-Alanine  
CAS RN: 338-69-2

**M0099** 25g 100g 500g




L-Methionine  
CAS RN: 63-68-3

**B3398** 1g 5g




O-tert-Butyl-L-threonine  
CAS RN: 4378-13-6

**T0539** 5g 25g




D-Tryptophan  
CAS RN: 153-94-6

**P0135** 5g 25g




D-Phenylalanine  
CAS RN: 673-06-3

**T0230** 25g 100g 500g



L-(+)-Threonine  
CAS RN: 72-19-5


**T0228** 25g 100g 500g



D-(+)-Threonine  
CAS RN: 632-20-2


## Cinchona Alkaloids

**C0347** 25g 100g




Cinchonidine  
CAS RN: 485-71-2

**C0348** 25g




Cinchonidine Dihydrochloride  
CAS RN: 24302-67-8

**C0349** 25g 500g



Cinchonidine Sulfate Dihydrate  
CAS RN: 524-61-8

**C0350** 25g 200g




Cinchonine  
CAS RN: 118-10-5

**C2728** 100mg




N-[(9S)-8α-Cinchonan-9-yl]-quinoline-8-sulfonamide  
CAS RN: 1440939-88-7

**H0752** 25g 250g




Hydroquinidine Hydrochloride  
CAS RN: 1476-98-8

**E0974** 100mg




α-Isocupreine  
CAS RN: 1476067-44-3

**H1701** 1g 5g




Hydrocinchonine  
CAS RN: 485-65-4

**H1702** 1g 5g




Hydrocinchonidine  
CAS RN: 485-64-3

**I0728** 1g




β-Isocupreidine  
CAS RN: 253430-48-7

**Q0006** 5g 25g




Quinidine  
CAS RN: 56-54-2

**Q0010** 5g 25g




Quinidine Sulfate Dihydrate  
CAS RN: 6591-63-5

**Q0028** 25g 100g




Quinine  
CAS RN: 130-95-0

**Q0030** 25g




Quinine Hydrochloride Dihydrate  
CAS RN: 6119-47-7

**Q0074** 100mg 1g





Quincorine  
CAS RN: 207129-35-9

**Q0076** 100mg 1g








Quincordine  
CAS RN: 207129-36-0





## Chiral Imidazolidinones
















## Chiral Oxazaborolidines



## Chiral Isothioureas




## Chiral Diols



## Chiral Phosphoric Acids


**B1144** 100mg 1g



(S)-(-)-1,1'-Binaphthyl-2,2'-diyl Hydrogen Phosphate  
CAS RN: 35193-64-7

**M2765**


50mg



(S)-3-[1-(4-Methoxybenzenesulfonyl)-(4S,5S)-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-yl]-1,1'-binaphthalene-2,2'-diyl Hydrogen Phosphate  
CAS RN: 1621994-95-3

**B1143**


100mg 1g 5g



(R)-(-)-1,1'-Binaphthyl-2,2'-diyl Hydrogen Phosphate  
CAS RN: 39648-67-4


## Chiral Sulfonic Acids

**C0015** 25g 100g 500g



(+)-10-Camphorsulfonic Acid  
CAS RN: 3144-16-9


**C0972** 25g 100g 500g



(-)-10-Camphorsulfonic Acid  
CAS RN: 35963-20-3

**D4445**


100mg



Dipotassium (R)-1,1'-Binaphthyl-2,2'-disulfonate  
CAS RN: 1092934-19-4

## Chiral Amines


**D4663** 20mg



N-[11bS]-4,5-Dihydro-3H-dinaphtho[2,1-c:1',2'-e]azepin-2-yl]-trifluoromethanesulfonamide  
CAS RN: 871915-77-4

**E1267**


50mg



Ethyl (11bR)-4-Amino-2,6-bis(3,5-di-tert-butylphenyl)-4,5-dihydro-3H-cyclohepta[1,2-a:7,6-a']dinaphthalene-4-carboxylate  
CAS RN: 1678540-23-2

**P2380**

50mg




(S)-[4-(Pyridin-4-yl)-4,5-dihydro-3H-dinaphtho[2,1-c:1',2'-e]azepine-2,6-diyl]bis[bis[4-(tert-butyl)phenyl]methanol]  
CAS RN: 1883396-49-3

## Chiral Ammonium Salts

**B3970**


50mg



(11bS)-2,6-Bis[bis[3,5-bis(trifluoromethyl)phenyl]hydroxymethyl]-3,5-dihydrospiro[4H-dinaphth[2,1-c:1',2'-e]azepine-4,4'-morpholinium] Bromide  
CAS RN: 1197922-04-5

**D3475**


200mg 1g



(R,R)-TaDiAS-2nd  
CAS RN: 2010983-27-2

**D3476**

200mg 1g




(S,S)-TaDiAS-2nd  
CAS RN: 2135524-59-1

## Chiral N-Heterocyclic Carbenes (NHC)

**B3592**


200mg 1g





(R)-Benzyl-2-[4-(trifluoromethyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolium Tetrafluoroborate  
CAS RN: 862095-77-0

**D3984**






100mg



Bode Catalyst 1 Monohydrate  
CAS RN: 919102-70-8



## Others



---

## Ordering and Customer Service

### TCI AMERICA

Tel : 800-423-8616 / 503-283-1681  
Fax : 888-520-1075 / 503-283-1987  
E-mail : Sales-US@TCIchemicals.com

### TCI EUROPE N.V.

Tel : +32 (0)3 735 07 00  
Fax : +32 (0)3 735 07 01  
E-mail : Sales-EU@TCIchemicals.com

### TCI Deutschland GmbH

Tel : +49 (0)6196 64053-00  
Fax : +49 (0)6196 64053-01  
E-mail : Sales-DE@TCIchemicals.com

### Tokyo Chemical Industry UK Ltd.

Tel : +44 (0)1865 784560  
E-mail : Sales-UK@TCIchemicals.com

### TCI Chemicals (India) Pvt. Ltd.

Tel : 1800 425 7889 / 044-2262 0909  
Fax : 044-2262 8902  
E-mail : Sales-IN@TCIchemicals.com

### 梯希爱(上海)化成工业发展有限公司

Tel : 800-988-0390 / 021-67121386  
Fax : 021-6712-1385  
E-mail : Sales-CN@TCIchemicals.com

### TOKYO CHEMICAL INDUSTRY CO., LTD.

Tel : +81 (0)3-5640-8878  
E-mail : globalbusiness@TCIchemicals.com

Availability, price or specification of the listed products are subject to change without prior notice. Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd.